Novo Nordisk to increase supply of weight-loss drug Wegovy

• Novo Nordisk is increasing the supply of Wegovy in the U.S., a weight-loss drug previously limited due to high demand.
• Wegovy, approved by the FDA for chronic weight management, is a semaglutide-based medication that assists in appetite regulation and blood sugar control.
• Despite increased production, Wegovy still faces accessibility issues due to high costs and inadequate insurance coverage.
• The market has seen new competition with the introduction of Eli Lilly's Zepbound, another obesity treatment drug.
• The challenges in continuous treatment include drug shortages and the need for better access to obesity medications for eligible patients.